Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024
July 24 2024 - 12:00PM
UK Regulatory
Oxurion Announces Results on the Extraordinary General Meeting
(EGM) of 24 July 2024
Oxurion Announces Results on the
Extraordinary General Meeting (EGM) of 24 July 2024
Leuven, BELGIUM – 24 July, 2024 – 06.00
PM CET – Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company headquartered in Leuven, held an
Extraordinary General Meeting on July 24, 2024. The shareholders
approved all items on the agenda of the Extraordinary General
Meeting.
All documents pertaining to the Extraordinary
General Meeting held on July 24, 2024, can be consulted on
Oxurion’s website Oxurion/shareholders.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in
developing next-generation standard of care ophthalmic therapies
for the treatment of retinal disease. Oxurion is based in Leuven,
Belgium. More information is available at www.oxurion.com.
Please contact for additional information:
Oxurion NV
Pascal Ghoson
Chief Executive Officer
pascal.ghoson@oxurion.com
|
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Dec 2023 to Dec 2024
